GOVX stock forecast 2025 is being shaped by macro trends in biotech funding. Equity research notes that risk-adjusted net present value models place fair value near $4.50, assuming prompt regulatory filings and sustained R&D productivity. SNL returns swinging as Trump sketch rips into wars, late ... Today, I want to focus on stocks trading under $10 with Wall Street analyst’s buy recommendations. Govx stock forecast 2025 points to potential volatility as biotech valuations remain sensitive to clinical trial outcomes. Analysts tracking NASDAQ small-cap biotech names suggest GOVX could trade in the $3.20–$5.80 range if upcoming vaccine-related data in late 2024 meets market expectations.
